


### Amendments to the Claims

1. (Original) A compound represented by the formula (I)




wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each represents a lower alkyl group.

2. (Original) The compound as claimed in Claim 1, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each represents an alkyl group having 3 or 4 carbon atoms.

3. (Original) (3S)-N-butyl-3-((2S)-2-(((4-fluorophenyl)sulfonyl)amino)-3-methylbutanoylamino)-5-methyl-2-oxohexanamide.

4-6. (Cancelled)


<sup>4</sup>  
4. (Original) A pharmaceutical composition comprising a compound represented by the formula (I)



wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each represents a lower alkyl group, and a pharmaceutically acceptable carrier.

<sup>5</sup>  
5. (Original) The pharmaceutical composition as claimed in Claim <sup>4</sup>4, which is a calpain inhibitor.

6  
8. (Original) A method for the treatment of a disease related to calpain, which comprises administering an effective amount of a compound represented by the formula (I)



wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each represents a lower alkyl group, to a mammal in need of treatment.

10. (Cancelled)